Ian Storer
Vice President of Hit Discovery & Open Innovation AstraZeneca
Ian leads the Global Hit Discovery and Open Innovation department within Biopharmaceuticals R&D at AstraZeneca, driving the identification and validation of high-quality starting points for innovative medicines across all therapeutic areas. With extensive cross-modality drug discovery experience from target validation through to clinical candidate selection, he champions a scalable, AI-enabled discovery engine and fosters public–private partnerships through AstraZeneca’s Open Innovation platform, while contributing to cross-industry initiatives including the European Innovative Health Initiative and the Structural Genomics Consortium.
Seminars
Thursday 30th July 2026
Evolving AI-Enabled Hit Discovery: Balancing Prediction, Screening & Data Collaboration
3:00 pm
- Providing a strategic perspective on how virtual screening and generative AI are reshaping hit identification and early optimization across global discovery programs
- Highlighting the interface between structural biology with hit discovery to validate binding hypotheses and guide early series expansion
- Outlining data strategy priorities, including expanding experimentally validated binding datasets through internal coordination and pre-competitive collaboration
